{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Buyyounouski MK"],"funding":["NCI NIH HHS"],"pagination":["584-591"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10941019"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(5)"],"pubmed_abstract":["<h4>Importance</h4>No prior trial has compared hypofractionated postprostatectomy radiotherapy (HYPORT) to conventionally fractionated postprostatectomy (COPORT) in patients primarily treated with prostatectomy.<h4>Objective</h4>To determine if HYPORT is noninferior to COPORT for patient-reported genitourinary (GU) and gastrointestinal (GI) symptoms at 2 years.<h4>Design, setting, and participants</h4>In this phase 3 randomized clinical trial, patients with a detectable prostate-specific antigen (PSA; ≥0.1 ng/mL) postprostatectomy with pT2/3pNX/0 disease or an undetectable PSA (<0.1 ng/mL) with either pT3 disease or pT2 disease with a positive surgical margin were recruited from 93 academic, community-based, and tertiary medical sites in the US and Canada. Between June 2017 and July 2018, "],"journal":["JAMA oncology"],"pubmed_title":["Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial."],"pmcid":["PMC10941019"],"funding_grant_id":["UG1 CA189867","U24 CA180803","U10 CA180868","P30 CA093373","U10 CA180822","UG1 CA233340"],"pubmed_authors":["Schroeder TM","Pugh SL","Feng F","Buyyounouski MK","Michalski JM","Barkati M","Sandler HM","Mann MJ","Vigneault E","Duncan CE","Konski AA","Valicenti RK","Mian OY","Monitto DC","Chen RC","Lawton CAF","Hannan R","Kudchadker RJ","Potters L","Rodgers JP","Kittel JA"],"additional_accession":[]},"is_claimable":false,"name":"Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.","description":"<h4>Importance</h4>No prior trial has compared hypofractionated postprostatectomy radiotherapy (HYPORT) to conventionally fractionated postprostatectomy (COPORT) in patients primarily treated with prostatectomy.<h4>Objective</h4>To determine if HYPORT is noninferior to COPORT for patient-reported genitourinary (GU) and gastrointestinal (GI) symptoms at 2 years.<h4>Design, setting, and participants</h4>In this phase 3 randomized clinical trial, patients with a detectable prostate-specific antigen (PSA; ≥0.1 ng/mL) postprostatectomy with pT2/3pNX/0 disease or an undetectable PSA (<0.1 ng/mL) with either pT3 disease or pT2 disease with a positive surgical margin were recruited from 93 academic, community-based, and tertiary medical sites in the US and Canada. Between June 2017 and July 2018, ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-02T18:05:43.572Z","creation":"2025-04-04T13:11:28.461Z"},"accession":"S-EPMC10941019","cross_references":{"pubmed":["38483412"],"doi":["10.1001/jamaoncol.2023.7291"]}}